A clinical and evidence-based review of the role of mesotherapy in non-surgical hair restoration

 

Author: Shannel Watson, MSc

Published: October 2025

 

Keywords: Alopecia, Alopecia Areata, Alopecia Ophiasis, Androgenetic Alopecia, Dutasteride, Exosome Therapy, Hair Loss, Hair Loss Treatment, Injectable Treatment, Male Pattern Hair Loss, Mesotherapy, Minoxidil, Platelet Rich Plasma, Scarring Alopecia, Telogen Effluvium

 

Download full PDF / Size: 1.2MB / Pages: 27

 

Abstract

Mesotherapy is increasingly used in the management of hair loss, with a growing body of evidence supporting its role in various clinical contexts. Platelet-rich plasma and emerging biologic preparations, such as exosomes, are often delivered using mesotherapy-style microinjections or microneedling, but mesotherapy remains a distinct modality. It traditionally involves the targeted delivery of nutrients, peptides, or biomimetic compounds into the scalp to support follicular activity, barrier function, or vascular supply.

This review explores the mechanisms of action, evaluates trial data, and highlights the clinical contexts in which mesotherapy appears most effective, particularly in androgenetic alopecia and telogen effluvium. Key ingredients are assessed for their biological plausibility: hyaluronic acid for hydration and barrier repair; copper peptides and growth factors for angiogenesis and anagen support; caffeine for androgen-mediated miniaturisation; botanicals with local 5α-reductase modulation; and vascular-targeted agents such as intradermal minoxidil, dutasteride, and botulinum toxin, which act through enhanced circulation, local androgen suppression and improved follicular oxygenation.

Clinical outcomes from published trials show improvements in hair density and shaft thickness after 3–6 sessions, with transient pain and erythema the most frequently reported adverse effects. However, protocol heterogeneity and small sample sizes limit generalisability. Evidence in alopecia areata remains preliminary, while in scarring alopecias, particularly those with active autoimmune activity, mesotherapy has no proven usefulness and should not be employed.

With appropriate diagnostic workup, patient selection, and compound selection, mesotherapy can yield measurable results as a standalone intervention. It is equally valuable as part of a layered therapeutic strategy, where addressing systemic drivers of hair loss is essential. Adjunctive measures such as nutrition counselling, correction of clinical (and subclinical) deficiencies, topical minoxidil, oral dutasteride, red light therapy and blue light therapy can enhance outcomes and support sustained success in non-surgical hair restoration.

Executive Summary

What is Mesotherapy?

Mesotherapy is a minimally invasive hair and scalp treatment in which biopreparations are injected into the dermis, sometimes referred to as the mesoderm in clinical literature. The intention is to deliver a concentrated dose of nutrients or compounds such as growth factors, biomimetic peptides, or scaffolding elements like cross-linked hyaluronic acid directly into the perifollicular niche. By reaching this compartment, mesotherapy may support hydration, stimulate angiogenesis, modulate keratinocyte activity, prolong the anagen growth phase to help reduce premature shedding and potentially reverse hair loss.

 

Current Applications and Evidence

Mesotherapy is most commonly applied in androgenic alopecia and telogen effluvium, where early studies suggest it may support follicular function, dermal hydration, and angiogenesis. Its use has also been explored in conditions such as dry scalp or seborrhoeic dermatitis, where hydration-focused formulations may improve comfort and barrier integrity. However, these are considered adjunctive rather than primary treatments.

Overall, positive trends have been reported, with several controlled trials demonstrating improvements in hair density, shaft diameter, and patient satisfaction, particularly when treatment is applied early and systemic factors are addressed. Differences in injection depth, frequency, compound selection, and integration alongside other therapies contribute to variability in findings. Although many mesotherapy preparations are not formally standardised or regulated as medicinal products, some are sold as licensed medical devices, and prescription-only compounds such as dutasteride can be incorporated off-label or purchased when administered by qualified medical professionals. The emerging data indicate that mesotherapy can offer clinical benefit when protocols are individualised and applied with diagnostic precision.

 

Patient Selection

Mesotherapy should only be offered after careful screening to exclude unsuitable candidates. Contraindications include active scalp infection or inflammation, uncontrolled inflammatory disease, poor wound-healing potential, and scarring alopecias such as lichen planopilaris or frontal fibrosing alopecia in their active phase, where injections risk worsening inflammation or accelerating fibrosis. Once these exclusions are ruled out, appropriate candidates include patients with viable follicles and a clinically stable background, with no untreated drivers of shedding such as iron deficiency, thyroid imbalance, vitamin D deficiency or uncontrolled diabetes. The most suitable presentations are early androgenic alopecia and telogen effluvium   after systemic factors have been corrected, or scalp conditions where barrier support can improve tolerance of wider therapy.

 

Proposed Protocol Framework for Mesotherapy in Hair Loss

Mesotherapy should follow a structured process: exclude active disease and systemic drivers, confirm follicle viability, and document baselines. Use appropriate depths and angles to target hydration, nutrient support, or follicular stimulation. Select preparations that align with the indication, and consider incorporating adjuncts such as minoxidil, red or blue light therapy, massage, dietary supplements, and nutritional adjustments.

Opportunities and Limitations

The available studies suggest that mesotherapy offers biological opportunities through direct delivery of nutrients, peptides, hydrating agents, and selected prescription compounds into the follicular niche, with potential to enhance angiogenesis, prolong the anagen phase, and improve scalp barrier function. These mechanisms align with observed positive trends in hair density, shaft diameter, and patient satisfaction when treatment is applied early and systemic drivers are addressed.

Nonetheless, most published trials remain small, heterogeneous in design, and limited by inadequate stratification of patient populations. Larger, standardised studies are needed to clarify efficacy, optimise protocols, and define where mesotherapy sits within evidence-based treatment pathways.

 

Aim of This White Paper

This white paper translates mesotherapy mechanisms into practical clinical guidance.  It reviews the biological rationale and available evidence, sets out baseline and safety criteria, details injection depths and angles, proposes a standard protocol system, maps adjunctive strategies to clinical features, and includes a neutral patient-facing Q&A section. It aims to promote consistent, safe, and auditable practice while clarifying where evidence is strong, where it is weak, and where further research is needed.

 

  

Definitions and Abbreviations

 

Mesotherapy

A technique involving multiple microinjections into the scalp

 

Androgenetic Alopecia (AGA)

A common type of hair loss, also known as male or female pattern baldness, characterised by progressive follicular miniaturisation under the influence of dihydrotestosterone.

 

Alopecia Areata (AA)

An autoimmune, non-scarring hair loss disorder presenting as well-demarcated patches of hair loss. Thought to be driven by an immune attack on the hair follicle.

 

Telogen Effluvium (TE)

Characterised by an abnormal shift of hair follicles from the anagen (growth) phase into the telogen (resting) phase. It is commonly triggered by systemic stressors such as illness, surgery, medications, hormonal changes, or nutritional deficiency. Acute telogen effluvium typically occurs 2–3 months after a trigger and resolves within 6 months, while chronic telogen effluvium persists beyond this period, can involve follicle miniaturisation and is often multifactorial. Follicles remain structurally intact, allowing for potential regrowth once underlying drivers are corrected.

 

Platelet-Rich Plasma (PRP)

An autologous preparation of plasma containing concentrated platelets (typically 3–5× baseline). Upon activation, platelets release growth factors such as vascular epithelial growth factor, platelet-derived growth factor and insulin-like growth factor that promote angiogenesis, matrix remodelling, and follicular cycling.

 

Exosomes

Nano-sized extracellular vesicles secreted by cells that contain proteins, lipids, and RNA. In trichology, experimental use focuses on modulating follicular inflammation and promoting regenerative signalling.

 

 

Table of Contents

 

·       1.0 Introduction: Mesotherapy, mechanisms, and evidence for hair loss

·         1.1 Historical background

·         1.2 Skin layers and scalp structures

·         1.3 Clinical trials and reported outcomes

·       2.0 Practical framework

·         2.1 Opportunities and limitations

·         2.2 Safety and considerations

·         2.3 Injection parameters depth gauge and angle

·         2.4 Matching mesotherapy ingredients to clinical features

·         2.5 Adjunctive therapies and their impact

·         2.6 Injectable pathways in context: PRP, exosomes and mesotherapy

·         2.7 Clinical implementation summary

·       3.0 Mesotherapy for hair loss: FAQs

·       4.0 Conclusion.

 

1.0 Introduction: Mesotherapy, mechanisms, and evidence for hair Loss

1.1 Historical background

Mesotherapy originated in mid-twentieth-century France, attributed to Dr Michel Pistor, who described intradermal microinjections for analgesia and complaints related to circulation. Over the subsequent decades, the approach evolved into aesthetic, hair, and scalp indications as formulations progressed from simple analgesics to combinations of vitamins, minerals, amino acids, hyaluronic acid, and peptides.

 

1.2 Skin layers and scalp structures

The scalp is composed of three principal layers: the epidermis, dermis, and hypodermis, each contributing to barrier function, elasticity, and vascular support (Elias and Steinhoff, 2008). Within the dermis and hypodermis sit the specialised structures of the hair follicle, including the dermal papilla, bulge stem cell niche, arrector pili muscle, sebaceous gland, and hair canal. These elements function as a unit regulating follicular cycling, anchorage, and environmental protection. The bulge houses multipotent stem cells that replenish follicular lineages. The dermal papilla provides inductive signalling for anagen initiation. Sebaceous glands secrete lipids critical for barrier integrity, and the arrector pili muscle links follicles to dermal and  vascular networks (Cotsarelis, 2006; Schneider et al., 2009). Disruption in any of these compartments can alter hair growth potential, stability, and tissue homeostasis (figure 1.1).

The epidermis is composed of keratinocytes, melanocytes, and immune cells. It provides a barrier but is too superficial to directly influence hair follicle growth. However, optimising barrier integrity in mesotherapy focuses on alleviating scalp dryness and discomfort. Preparations that include hydrating agents such as hyaluronic acid or lipid-replenishing components like ceramides may help restore the epidermal barrier, reduce transepidermal water loss, and support a more stable scalp environment for hair growth (Elias and Steinhoff, 2008).

The dermis is composed of blood vessels, fibroblasts, and collagen. With age and conditions such as androgenetic alopecia (AGA), collagen turnover decreases, type I collagen declines, and type III collagen accumulates, leading to dermal stiffening, reduced elasticity, and impaired blood flow. This environment can limit follicular nutrition and survival (Varani et al. 2006; Won et al. 2008). Similar changes may also occur in chronic scalp inflammation or in deficiency states such as zinc deficiency, which impairs collagen synthesis and wound healing (Yang, 2024). Mesotherapy preparations that include cross-linked hyaluronic acid may help counteract this process by improving dermal hydration, supporting extracellular matrix (ECM) remodelling, and restoring conditions more conducive to follicular survival (Quan et al. 2013; Harries et al. 2010). 

The hypodermis (subcutaneous layer) cushions and supports follicles, contains vascular networks, and supplies adipose-derived growth factors. In AGA, subcutaneous tissue volume decreases, reducing vascular and trophic support (Soga et al., 2021). Dihydrotestosterone (DHT) is strongly implicated, altering fibroblast behaviour and accelerating follicular miniaturisation (Kaufman, 2002). Beyond DHT, other hormonal and systemic influences also contribute.

Low estrogen levels are associated with reduced subcutaneous thickness, as seen in postmenopausal women and in polycystic ovary syndrome (PCOS) where hormone balance is disrupted (Steiner and Berry, 2002; Yang and Chen, 2024). Elevated cortisol has also been linked to impaired adipose tissue maintenance and vascular function in systemic studies (Kelly et al., 1998). While not scalp-specific, this evidence can be reasonably extrapolated to suggest that chronic stress may weaken hypodermal support in the scalp.  These combined factors suggest that hypodermal changes are not exclusively androgen-driven but rather reflect broader endocrine and metabolic interactions.

Mesotherapy does not aim to inject into the hypodermis; delivery is targeted to the superficial to mid dermis, where follicular structures and perifollicular vasculature reside. However, its rationale partly rests on counteracting hypodermal decline indirectly, by improving dermal vascularisation and supporting follicular nutrition. Preparations may include angiogenic or pro-repair peptides such as vascular endothelial growth factor (VEGF)-mimetic peptides, insulin-like growth factor 1 (IGF-1) analogues, or copper peptides (GHK-Cu), alongside hyaluronic acid and vitamins, to stimulate angiogenesis, modulate keratinocyte activity, and improve ECM integrity (Md Fadilah, 2024).

The bulge stem cell niche is located in the outer root sheath, where the arrector pili muscle attaches to the follicle. It contains multipotent epithelial stem cells that replenish the follicle during each cycle. Signals from the dermal papilla, immune cells, and adipocytes regulate stem cell activity (Hsu, 2011). Mesotherapy may support this environment by improving angiogenesis with VEGF-mimetic peptides, providing matrix scaffolding with hyaluronic acid, and reducing oxidative stress through antioxidant inclusions, all of which could sustain stem cell activation.

The dermal papilla at the follicle base is a cluster of fibroblasts critical for inducing anagen and regulating follicle size (Jahoda, 1984). Agents that enhance vascularisation, such as copper peptides or biomimetic growth factors, may increase nutrient and oxygen delivery to this region, prolonging the anagen phase.

The sebaceous gland produces sebum that maintains barrier function and follicle flexibility.  Mesotherapy with hydrating agents (e.g., hyaluronic acid) or antioxidants could indirectly improve sebaceous gland homeostasis, though no direct clinical data exist.

The arrector pili muscle connects the bulge niche to the dermis. Loss of this connection has been implicated in follicular miniaturisation (Torkamani, 2017). While mesotherapy does not restore muscle integrity, it may reduce perifollicular fibrosis via matrix remodelling peptides, indirectly preserving this anatomical link.

The inner root sheath and hair canal provide structural guidance as the shaft emerges through the epidermis. Barrier-supportive mesotherapy components, such as ceramides or cross-linked hyaluronic acid, could help maintain canal integrity and reduce irritation, though evidence remains anecdotal.

Clinical implications. From a practical standpoint, injection depth determines whether an agent reaches the papillary dermis (0.25–0.5 mm, relevant for barrier modulation and hydration), mid-dermis (1–2 mm, relevant for follicular and vascular support), or deeper reticular dermis to upper hypodermis (2–4 mm, relevant where fibrosis or atrophy has reduced tissue elasticity). Selection of needle length and angle must therefore be aligned with the pathology targeted.

 

 

 

Figure 1.1 Cross-section of the scalp

1.3 Clinical trials and reported outcomes

The body of literature evaluating mesotherapy for AGA and telogen TE reflects a heterogeneous yet increasingly structured field, where injectable agents are emerging as adjunctive or alternative strategies to conventional therapies such as oral finasteride and topical minoxidil. A recent systematic review identified 27 eligible studies, including 10 randomised controlled trials, one non-randomised controlled trial, and a range of observational and case-based reports. In the present analysis, emphasis is placed on the randomised controlled trials; however, only nine are detailed here, as one study evaluated mesotherapy solely as a comparator arm rather than a standalone intervention (Gupta, 2023). Across these, key methodological trends and efficacy patterns offer insight into the clinical value and limitations of this therapeutic modality.

Among the trials reviewed, Abdallah (2009) and Sobhy et al. (2013) stand out for their robust design, both employing dutasteride-based injectable solutions. Abdallah’s study used a commercial preparation containing dutasteride alongside biotin, pyridoxine, and panthenol, with hair count assessed at a fixed vertex location using a standardised template. The method enabled reproducible and objective quantification, supported by blinded photographic evaluation and patient self-assessment. The increase in hair count in the active group (+7.7 hairs/ cm²) was statistically significant and clinically meaningful, while the placebo group showed a marginal decrease. Importantly, this study demonstrated that earlier stages of baldness and shorter durations of hair loss were associated with better outcomes, reinforcing the importance of early intervention. Sobhy’s trial compared pure dutasteride, a dutasteride-vitamin combination, and placebo across nine sessions, incorporating trichogram analysis and hormonal evaluation (serum DHT and semen parameters). The group receiving the combination formulation demonstrated superior improvements in the anagen-to-telogen ratio, hair shaft diameter, and overall patient satisfaction. The inclusion of semen analysis and DHT measurement added a mechanistic layer to the findings, providing reassurance regarding systemic absorption and safety.

Several studies explored the utility of peptide-based mesotherapy solutions. Shome (2021) reported on QR678 Neo®, a proprietary polypeptide formulation, in a year-long prospective study. The formulation significantly improved hair parameters, including terminal hair count and shaft diameter, with greater gains observed when combined with topical minoxidil and oral finasteride. This supports the hypothesis that mesotherapy, while valuable, may be most effective when integrated into a multimodal regimen. Similarly, Nassar (2022) demonstrated that LC Hair Essence, comprising hyaluronic acid, stem cell peptides, red clover extract, and zinc arginine, yielded significant improvement in AGA patients with results comparable to botulinum toxin A, with fewer reported side effects and higher patient tolerance. The use of trichoscopy and monthly documentation allowed for high-resolution tracking of hair changes over time.  However, it is worth noting that Nassar diluted the peptide solution with 0.5 mL of 0.9% saline for a 1 mL final solution.  This is despite it being a commercial preparation that did not require dilution, an adjustment that may have influenced overall efficacy outcomes.

Minoxidil, traditionally administered topically, has also been evaluated as a mesotherapy agent. Azam (2010) and Uzel (2021) provided evidence that intradermal minoxidil may be more effective than topical application, particularly in reducing vellus hair and increasing the percentage of hairs in anagen phase. Uzel’s placebo-controlled trial, which employed biopsy, trichogram, Trichoscan analysis, and self-reporting, observed statistically significant improvements in hair density and volume, suggesting that localised delivery may enhance follicular responsiveness.

Some trials, including those by Gajjar (2019) and Hunter (2019), yielded more modest results, possibly due to shorter follow-up durations or smaller sample sizes. Gajjar reported an increase in hair shaft diameter with peptide-based mesotherapy but found no significant changes in other parameters. Hunter’s blinded study noted that while 67.6% of patients in the mesotherapy group reported subjective improvement, the between-group difference was marginal (p = 0.056).  However, objective measures told a clearer story: the mesotherapy group showed a statistically significant increase in the number of hair follicles (p = 0.001), underscoring a meaningful biological response, even when subjective differences were less pronounced at week 12.  An increase in follicle count remains one of the most promising indicators of treatment efficacy.

In the context of TE, Khattab (2022) explored the use of multivitamin mesotherapy versus single-session botulinum toxin A injections. Both modalities were effective in improving hair density, although botulinum toxin A was favoured for simplicity of administration. However, the mesotherapy group demonstrated better anchoring of follicular units, suggesting deeper follicular engagement. This aligns with emerging hypotheses that mesotherapy may exert effects not only through active ingredients but also via mechanical or immunomodulatory signalling within the dermal papilla.

Collectively, the trials highlight that mesotherapy is an increasingly validated therapeutic approach. The strongest clinical results were consistently observed in studies using dutasteride-based cocktails or proprietary peptide blends, especially when evaluated over extended periods and measured using objective modalities such as trichogram or high-resolution trichoscopy. While patient-reported outcomes were generally concordant with objective findings, they remain susceptible to perception bias and should be interpreted in conjunction with more rigorous endpoints.

One emerging theme is the importance of treatment timing. Several studies noted that the duration of hair loss and the stage of alopecia significantly influenced treatment response, with early-stage or shorter-duration cases responding more robustly. This has implications for patient counselling and highlights the need for early diagnostic clarity. Another key insight is that combination therapy, whether through systemic agents or topical applications, appears to enhance mesotherapy outcomes.

Although the safety profile across trials was generally favourable, standardised reporting of adverse events and systemic effects remains limited. Only one study included semen analysis and serum DHT levels, which are critical given the hormonal targets of agents like dutasteride and finasteride. More comprehensive biomarker profiling and imaging should be incorporated into future trials to elucidate both the mechanism and risk, particularly when using preparations that include prescription medications.

In summary, mesotherapy for hair loss shows promising efficacy. Dutasteride and growth-factor-rich peptide solutions consistently show the highest response rates, particularly when combined with other therapies and applied early in the disease course. However, the field would benefit from larger randomised controlled trials with standardised endpoints and long-term follow-up to substantiate its place in the therapeutic hierarchy for alopecia management.

 

2.0 Practical framework

 

2.1 Opportunities and limitations

Mesotherapy demonstrates clinically meaningful effects in AGA and TE, including as a standalone intervention. In several randomised trials, mesotherapy significantly improved hair count, terminal-to-vellus hair ratio, and hair shaft diameter without the need for adjunctive oral or topical agents (Abdallah et al., 2009; Sobhy et al., 2013; Uzel et al., 2020; Khattab et al., 2022). Notably, increases in shaft diameter, an early marker of follicular reactivation, were observed independently of combination therapy, indicating direct follicular effects via angiogenesis, modulation of inflammation, or activation of the Wnt/β-catenin pathway (Gajjar et al., 2019; Shome et al., 2021). Trials comparing mesotherapy to botulinum toxin A suggest similar or superior efficacy with fewer side effects and lower cost, further supporting its role as a primary rather than purely adjunctive modality (Nassar et al., 2022; Khattab et al., 2022).

Nevertheless, appropriate patient selection remains critical. Most studies exclude participants with systemic comorbidities such as thyroid disease, anaemia, androgen excess, anticoagulant use, or active scalp inflammation, conditions known to interfere with follicular cycling and healing capacity (Azam et al., 2010; Hunter et al., 2019; Sobhy et al., 2013). This highlights the importance of addressing nutritional deficiencies, endocrine imbalances, or chronic inflammatory states before initiating mesotherapy. Without this diagnostic groundwork, the rationale for choosing angiogenic, keratinogenic, or hydrating preparations becomes arbitrary, as the primary follicular barrier to health may remain unaddressed. When used within a structured care pathway that includes systemic correction, targeted delivery, and realistic expectations, mesotherapy offers an evidence-based therapeutic option in both standalone and combination formats (Gupta et al., 2023; Choi et al., 2016).

 

2.2 Safety considerations

Mesotherapy should not be undertaken in the presence of contraindications that significantly raise the risk of adverse outcomes. Active scalp infection, uncontrolled inflammatory dermatoses, and pregnancy are absolute exclusions (Sivagnanam, 2010). Systemic isotretinoin use is also contraindicated, given its recognised impact on wound healing and risk of abnormal scarring (McDonald et al., 2017). Patients with metabolic disease, such as poorly controlled diabetes or systemic autoimmune disorders, face a higher risk of delayed healing and exaggerated inflammatory responses and should therefore be excluded (Górska et al., 2024). Additional caution is advised in those with known coagulopathies or on anticoagulant therapy, where the risk of bleeding and bruising is amplified (Mammucari et al., 2025). Careful pre-treatment screening against these criteria ensures that mesotherapy is offered only to candidates with adequate healing capacity and stable systemic health, thereby improving both safety and tolerability.

  

2.3 Injection parameters depth gauge and angle

Depth selection should reflect the therapeutic target. Barrier modulation and comfort can be addressed at approximately 0.25 to 0.5 mm. Follicular and vascular interface targets commonly lie at approximately one to two millimetres in many scalp regions, adjusting for individual anatomy. Fibrotic bands may require a penetration depth of two to three millimetres in selected areas, with caution due to potential pain and vascular risk.

Needle gauge is typically thirty to thirty-two gauge for scalp mesotherapy. Short needles reduce leverage and discomfort. An adjustable depth device can reduce the need for multiple needles.

The injection angle should be shallow, approximately ten to thirty degrees, to remain within the dermis, particularly over thin bony areas. Space injections evenly and avoid intravascular administration by aspirating where appropriate and using low volumes per point: 0.01 to0.05 mL per injection point.

Deeper placement in the reticular dermis or upper hypodermis (approximately 2–4 mm) may be relevant in contexts where fibrosis or atrophy has reduced tissue elasticity.  These pathological changes justify occasional targeting of the deeper reticular dermis to upper hypodermis to deliver agents aimed at improving hydration, vascular support, or fibroblast activity, while avoiding deeper hypodermis placement.

2.4 Matching mesotherapy ingredients to clinical features

The therapeutic potential of mesotherapy lies not in indiscriminate use, but in matching ingredients to the underlying biology of hair loss and scalp conditions. Different domains of activity address distinct mechanisms, from hydration and barrier support to nutrient replacement, follicular stimulation, androgen modulation, dermal signalling, oxidative stress control and vascular enhancement. By organising mesotherapy options into these categories, clinicians can move toward a modular, evidence-aligned approach, selecting actives that correspond to each patient’s diagnostic profile rather than applying formulations generically.

Hydration and barrier support are best achieved with high-weight hyaluronic acid, which remains the most widely supported inclusion for hydration, barrier reinforcement, and scaffolding of co-delivered actives. This is particularly relevant in dry scalp, post-inflammatory states, or when dermal pliability is reduced (Papakonstantinou et al., 2012). Cross-linked hyaluronic acid extends the residence time of actives, while high-molecular-weight hyaluronic acid adds anti-inflammatory and protective effects.

Nutrient-based blends may provide local benefit during systemic or subclinical deficiencies. Amino acids and biotin are plausible cofactors in diffuse shedding associated with poor nutrition; however, the evidence outside of deficiency states remains modest (Patel et al., 2017; Rushton, 2002). Within this context, amino acids such as cysteine, methionine, lysine, and arginine provide the raw materials for keratin synthesis and the formation of follicular structure. Arginine enhances vascular delivery through nitric oxide production, N-acetyl-cysteine supports antioxidant defence, and glutamine or glutamic acid contributes nitrogen donor roles. Collectively, they may strengthen keratin infrastructure, improve scalp resilience, and reduce oxidative stress.

Stimulants such as caffeine represent one of the more biologically active inclusions. Caffeine has demonstrated consistent in vitro effects by counteracting DHT-induced follicular suppression, increasing intracellular cAMP through phosphodiesterase inhibition, and stimulating dermal papilla metabolism (Fischer et al., 2014). Beyond this, caffeine appears to upregulate growth factors such as IGF-1 in dermal papilla cells, effectively mimicking pro-anagen signals that protect follicle survival. While mesotherapy-specific data are lacking, topical studies suggest reduced shedding and anagen prolongation, making caffeine a plausible candidate in AGA, where miniaturisation is androgen-driven, and in TE, where follicular energy support may be beneficial.

Antiandrogens form another domain, aiming to reduce local DHT activity at the follicular level. Botanical agents such as saw palmetto and epigallocatechin gallate (EGCG) are occasionally included in mesotherapy blends for this purpose. Saw palmetto functions as a natural antiandrogen through competitive inhibition of DHT binding, while EGCG provides additional antioxidant and anti-inflammatory benefits that may support follicle protection in inflammatory scalp states. However, the durability and efficacy of these botanicals in injectable form remain unproven, as controlled mesotherapy trials are lacking (Sudeep et al., 2023; Kwon et al., 2007). Pharmaceutical 5α-reductase inhibitors, such as low-dose intradermal dutasteride (0.02–0.05%), provide a stronger evidence base, with trials showing durable regrowth in androgenetic alopecia, while minimising systemic exposure.

Peptide-based formulations carry one of the strongest mechanistic rationales because they deliver direct biological “messages” to cells. Copper peptides such as GHK-Cu stimulate fibroblasts, remodel extracellular matrix, and promote angiogenesis, while biomimetic growth factor peptides such as VEGF, PDGF, and IGF-1 extend anagen, enhance vascularisation, and activate dermal papilla cells (Pickart, 2018; Yano et al., 2001). Their targeted signalling makes them most suitable in early AGA, TE, traction alopecia with viable follicles, or post-inflammatory states requiring dermal remodelling.

Antioxidants also have a theoretical role in oxidative stress-associated shedding. Elevated oxidative stress markers are observed in AGA, alopecia areata, and chronic TE, implicating reactive oxygen species in miniaturisation and dermal papilla apoptosis. Small oral and topical studies of EGCG, vitamin E, resveratrol, and coenzyme Q10 show reductions in lipid peroxidation and improved hair fibre quality, supporting a rationale for mesotherapy delivery of antioxidants, even though injection trials are lacking.

Finally, vascular-targeted actives represent the most clinically validated domain. Intradermal minoxidil (0.5 - 2%) increases perifollicular blood flow and VEGF expression, stimulating anagen entry in AGA and stress-related TE. Dutasteride (0.02–0.05%) locally inhibits DHT, producing durable regrowth with lower systemic exposure, while botulinum toxin A in dilute microdoses relaxes scalp musculature, improves oxygenation, and may reduce perifollicular DHT activity. Together, these agents anchor mesotherapy as a credible therapeutic pathway for androgenetic alopecia.

In summary, mesotherapy should be viewed as a modular intervention, with preparation tailored to the clinical presentation: hydration for barrier repair, stimulants and botanicals for androgenic thinning, peptides for dermal support, antioxidants for oxidative stress states and barrier compromise, and vascular-targeted therapies for AGA and TE.

 

2.5 Adjunctive therapies and their impact

Pharmacological standards, such as minoxidil, remain first-line for sustaining anagen and reversing miniaturisation, while device-based therapies, like red and blue LED, provide additional support for mitochondrial function and the scalp microbiome (Kwon et al., 2023). Structured scalp massage, though low-tech, has been shown to stimulate dermal remodelling in fibrotic tissue and increase hair thickness in small trials. In one 24-week controlled trial of daily 4-minute scalp massage in nine healthy men, the authors reported measurable increases in hair thickness and gene expression changes in dermal papilla cells (e.g. upregulation of NOGGIN, BMP4, SMAD4) (Koyama et al., 2016).  When applied judiciously, massage can augment the effects of mesotherapy by priming circulation and mechanotransductive signalling, though it is not universally necessary.

 

2.6 Injectable pathways in context: PRP, exosomes, and mesotherapy

Mesotherapy, PRP, and exosomes are often discussed in the same clinical space, yet each represents a distinct category of intervention. Mesotherapy uses nutrient, peptide, or biomimetic formulations injected intradermally to support hydration, angiogenesis, or follicular signalling. Its flexibility is a strength, as preparations can be adjusted to patient needs and often incorporate stable synthetic peptides designed for slow release.

PRP is mechanistically different, as it is derived from autologous whole blood. Centrifugation concentrates platelets to three to five times the baseline level, typically yielding 1.0 to 1.5 million platelets per microliter. When activated, these platelets release a broad array of growth factors, including VEGF, PDGF, IGF-1, and transforming growth factor-β (TGF-β) (Gentile et al., 2015; Alves and Grimalt, 2016). These factors are biologically plausible drivers of angiogenesis and follicular activity, but their release is short-lived, as most degrade within hours to days.

Trials of PRP typically exclude patients with systemic illness, poorly controlled thyroid disease, anaemia, or other conditions that may impair platelet function or reduce growth factor yield. Notably, vitamin D deficiency and elevated HbA1c are both linked to impaired platelet responsiveness and vascular health (Alaniet al., 2020; Saluja, 2019). Such conditions may not only worsen hair loss but also limit the effectiveness of the PRP preparation itself. This creates a paradox: the populations most in need are least studied, and efficacy in these groups remains untested.

Exosomes represent a third approach. These extracellular vesicles, usually derived from mesenchymal stem cells, carry proteins, messenger RNA, and microRNAs that influence recipient cells by modulating inflammation, angiogenesis, and dermal papilla signalling. Unlike PRP, exosomes are not autologous, but are increasingly manufactured under controlled conditions, with some products advertising particle counts. Evidence suggests they may promote density and shaft thickness improvements, with early studies reporting increases of up to 35 hairs/cm² and shaft thickening of 10 to 13 µm over 3 to 6 months (Wan et al., 2025). Limitations remain: preparations vary by patient, long-term follow-up is rare, and it is not yet clear which molecular cargo is most important. Nonetheless, exosomes offer the appeal of consistency and a longer signalling window compared with the transient burst of PRP.

When comparing these modalities, the differences lie less in which is stronger and more in how they are produced, who they are tested on, and what mechanisms they realistically influence. PRP delivers an acute surge of native growth factors but is heavily dependent on the donor’s own physiology. Mesotherapy offers controlled, synthetic nudges designed for consistency but is under-evaluated clinically. Exosomes provide complex paracrine cues with increasing standardisation but little long-term safety data.

PRP should not be assumed effective across all hair loss conditions. In autoimmune or scarring alopecias, the inflammatory microenvironment may negate any short-lived angiogenic signal from platelet concentrates. Preparation technique is another critical variable: platelets tend to aggregate easily, and small deviations in centrifugation speed, aspiration method, or activation protocol can reduce their viability or alter the yield of growth factor release (de Melo, 2019).  These variables highlight the fragility of PRP as a therapeutic tool and help explain inconsistent results even in AGA.

By contrast, exosome and mesotherapy formulations are not derived from the patient’s own blood and can be manufactured to deliver standardised concentrations of peptides, growth factors, or signalling vesicles. This reduces some of the variability seen in PRP preparation. However, these interventions are still influenced by host biology. Systemic factors such as iron deficiency, vitamin D insufficiency, chronic inflammation, or hormonal imbalance may compromise tissue responsiveness and downstream signalling. In mesotherapy, the recipient’s nutritional status remains important. While the inclusion of vitamins and amino acids may offer support in cases of subclinical deficiency and outright deficiency, their therapeutic impact is limited if more significant underlying imbalances are unaddressed. As such, the effectiveness of mesotherapy still depends on appropriate patient selection and optimisation of systemic and local scalp conditions.

 

2.7 Clinical implementation summary

 Mesotherapy should be delivered using a structured approach to optimise safety, efficacy and reproducibility:

 

Pre-treatment assessment: Confirm that there is no active scalp inflammation or infection. Review systemic drivers, including but not limited to iron status, vitamin D, thyroid function, blood glucose and liver function, if risk factors are present. Baseline trichoscopy and photographic documentation are advised.

Patient consent: Informed consent should include discussion of expected outcomes, risks and time frames.

Injection technique: A 30 to 32 gauge needle is typically used. Depth depends on the therapeutic target: 0.25 to 0.5 mm for barrier and hydration support, 1 to 2 mm for follicular delivery, and up to 2.5 to 3 mm in fibrotic dermis. Angled entry between 30 and 45 degrees is standard, with perpendicular injection reserved for thickened or scarred areas.

Scheduling: Treatment is commonly administered every 2 to 4 weeks for 12 weeks. This initial phase can be considered as the 'loading phase'.  Chronic or more progressive cases of hair loss will benefit from an intensive loading phase, administered at a maximum of 1 treatment every 2 weeks for 12 weeks.  Mild cases of hair loss typically begin with sessions every 2 weeks for 6 weeks, then progress to sessions every 4 weeks. This loading phase can taper off into an 'optimisation phase' where there are sessions every 4 weeks for 3 to 6 months, depending on response at week 12.  Depending on the result and the individual, maintenance sessions can be scheduled every 3-6 months  

Formulation strategy: The preparation should match the dominant clinical goal. Options include hydration support, nutritional supplementation, follicular signalling or vascular support.

Adjunctive care: Supportive treatments such as topical minoxidil, light-based therapy and nutritional correction should be considered alongside mesotherapy where indicated.

Monitoring and stop rules: Reassess after 12 weeks using trichoscopy, patient-reported outcomes and clinical photography.  If no improvement at month 6, stop treatment.  Accurate documentation of outcomes supports audit, safety and future protocol refinement.

 

3.0 Mesotherapy for hair loss: FAQs

The following questions reflect common patient concerns and popular search queries about mesotherapy for hair loss, reframed with evidence-based answers to improve transparency and set realistic expectations.

 

Q: How many mesotherapy sessions are needed for results?

Most protocols recommend 3 to 6 sessions spaced every 2 to 4 weeks initially. Visible improvement usually begins after 3 months, and reassessment is advised at 3 months. Maintenance sessions may be needed every 3 to 6 months.

 

Q: How long does it take to see results?

Patients rarely notice visible changes before 12 weeks. Some shedding may continue initially before stabilising. 

 

Q: Can mesotherapy stop hair shedding immediately?

No. While some patients report early improvement, it may take more than one session to achieve a noticeable reduction in shedding.

 

Q: Is mesotherapy painful?

Most patients describe mild stinging or discomfort. The use of fine-gauge needles makes the procedure well-tolerated.  Sensation is usually brief and manageable.

 

Q: What are the side effects of mesotherapy?

Common side effects include redness, swelling, bruising, or tenderness. Rare complications may include infection, delayed healing, or scarring.  Side effects are typically mild and short-lived when good technique and safety screening are applied.

 

Q: Does mesotherapy work for androgenetic alopecia?

Men and women with early to moderate signs of hair loss are likely to benefit based on recent evidence.  All patients should undergo full baseline blood testing to identify and address correctable drivers of their current hair or scalp condition.

 

Q: Is mesotherapy safe for alopecia areata?

Mesotherapy is not recommended for active alopecia areata. This condition is better managed with anti-inflammatory strategies under a dermatologist’s or trichologist’s supervision.

 

Q: Can mesotherapy help with hair regrowth after chemotherapy?

Mesotherapy should not be used during chemotherapy. Mesotherapy may help stimulate regrowth 6 months after treatment cessation.

 

Q: Is mesotherapy better than minoxidil?

Not necessarily. Minoxidil is the most established treatment for AGA, with strong long-term data. However, mesotherapy may be equally or more appropriate in other forms of hair loss, such as TE or stabilised postpartum shedding. The two are often combined for enhanced results.  In early-stage androgenetic thinning, a combination of topical minoxidil and mesotherapy may offer the best response. In non-androgenic thinning, mesotherapy may be preferable as a more targeted intervention.

 

Q: Can mesotherapy be combined with red or blue light therapy?

Yes. Light therapy supports follicle metabolism and reduces inflammation. Combining it with mesotherapy may improve results and patient satisfaction.  While research is ongoing, this combination is frequently used in clinical settings to support regrowth.

Q: How long do the results from mesotherapy last?

Durability depends on lifestyle and systemic health.

 

Q: What do patients say about mesotherapy?

Most patients report improvement in hair texture, reduced shedding, or a general sense of thicker hair. However, satisfaction is highest when expectations are realistic, and the treatment is part of a broader plan.

 

4.0 Conclusion: Mesotherapy for hair loss and scalp health

Mesotherapy for hair loss is advancing toward a biologically targeted, evidence-based approach.  Hyaluronic acid can restore hydration and barrier function, while amino acids and biotin support recovery where nutritional shortfalls contribute to diffuse shedding. In androgen-driven conditions, caffeine, saw palmetto, EGCG, or intradermal dutasteride may help counter follicular miniaturisation.

Beyond support and modulation, mesotherapy now includes more advanced actives, such as peptides and growth factors, that deliver targeted molecular signals to extend anagen, stimulate angiogenesis, and remodel the dermis. Antioxidants offer a plausible route for reducing oxidative stress and supporting barrier function.  

When these domains are applied with diagnostic precision, mesotherapy shifts from empiricism to an integrated, evidence-aligned strategy. Mesotherapy holds promise as a clinically valuable addition to the field of personalised hair restoration.

 

Download full PDF / Size: 1.2MB / Pages: 27

 

 

References

 

Abdallah, M., El-Zawahry, K.A. and Besar, H., 2009. Mesotherapy using dutasteride-containing solution in male pattern hair loss: a controlled pilot study. J Pan Arab Leag Dermatol, 20, pp.137-145.

 

Alanli, R., KÜÇÜKAY, M. and YALÇIN, K., 2020. Relationship between vitamin D levels and platelet count: A retrospective study. Gulhane Medical Journal, 62(3).

 

Alves, R. and Grimalt, R., 2016. Randomised, placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia. Dermatologic Surgery, 42(4), pp.491-497.

 

Azam, M.H. and Morsi, H.M., 2010. Comparative Study Between 2% Minoxidil Topical Spray vs. Intradermal Injection (Mesotherapy) for Treatment of Androgenetic Alopecia in Female Patients: A Controlled, 4-month Randomized Trial. Egyptian Dermatology Online Journal, 6(2), p.5.

 

Choi, J.W., Loh, S.H., Lew, B.L. and Sim, W.Y., 2016. Histopathologic features of ophiasis-type alopecia areata. J Am Acad Dermatol, 76(6), pp.AB156-c.

 

Cotsarelis, G. 2006. Epithelial stem cells: A folliculocentric view. Journal of Cell Science, 119(4), pp. 609–613.

 

de Melo, B.A.G., Luzo, Â.C.M., Lana, J.F.S.D. and Santana, M.H.A., 2019. Centrifugation conditions in the L-PRP preparation affect soluble factors release and mesenchymal stem cell proliferation in fibrin nanofibers. Molecules, 24(15), p.2729.

 

Elias, P.M. and Steinhoff, M., 2008. “Outside-to-inside”(and now back to “outside”) pathogenic mechanisms in atopic dermatitis. Journal of Investigative Dermatology, 128(5), pp.1067-1070.

 

Fischer, T.W., Herczeg‐Lisztes, E., Funk, W., Zillikens, D., Bíró, T. and Paus, R., 2014. Differential effects of caffeine on hair shaft elongation, matrix and outer root sheath keratinocyte proliferation, and transforming growth factor‐β2/insulin‐like growth factor‐1‐mediated regulation of the hair cycle in male and female human hair follicles in vitro. British Journal of Dermatology, 171(5), pp.1031-1043.

 

Gajjar, P.C., Mehta, H.H., Barvaliya, M. and Sonagra, B., 2019. Comparative study between mesotherapy and topical 5% minoxidil by dermoscopic evaluation for androgenic alopecia in males: a randomised controlled trial. International journal of trichology, 11(2), pp.58-67.

 

Gentile, P., Garcovich, S., Bielli, A., Scioli, M.G., Orlandi, A. and Cervelli, V., 2015. The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. Stem cells translational medicine, 4(11), pp.1317-1323.Górska, M., Kmak, B. and Szot, A., 2024. Autoimmune disease and aesthetic medicine: a holistic approach. Quality in Sport, 18, pp.53918-53918.

 

Gupta, A.K., Polla Ravi, S., Wang, T., Talukder, M., Starace, M. and Piraccini, B.M., 2023. Systematic review of mesotherapy: a novel avenue for the treatment of hair loss. Journal of Dermatological treatment, 34(1), p.2245084.

 

Harries, M.J. and Paus, R., 2010. The pathogenesis of primary cicatricial alopecias. The American journal of pathology, 177(5), pp.2152-2162.

 

Hunter, N., Sayed, K., Abdel Hay, R., Allam, R. and Hussein, N., 2019. Comparing the efficacy of mesotherapy to topical minoxidil in the treatment of female pattern hair loss using ultrasound biomicroscopy: a randomized controlled trial. Acta Dermatovenerologica Croatica, 27(1), pp.1-1.

 

Hsu, Y.C., Pasolli, H.A. and Fuchs, E., 2011. Dynamics between stem cells, niche, and progeny in the hair follicle. Cell, 144(1), pp.92-105.

 

Jahoda, C.A.B., Horne, K.A. and Oliver, R.F., 1984. Induction of hair growth by implantation of cultured dermal papilla cells. Nature, 311(5986), pp.560-562.

 

Johny, E., Jala, A., Nath, B., Alam, M.J., Kuladhipati, I., Das, R., Borkar, R.M. and Adela, R., 2022. Vitamin D supplementation modulates platelet-mediated inflammation in subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Frontiers in immunology, 13, p.869591.

 

Khattab, F.M., Rady, A. and Khashaba, S.A., 2022. Recent modalities in treatment of telogen effluvium: Comparative study. Dermatologic Therapy, 35(10), p.e15720.

 

Kaufman, K.D., 2002. Androgens and alopecia. Molecular and cellular endocrinology, 198(1-2), pp.89-95.

 

Kelly, J.J., Mangos, G., Williamson, P.M. and Whitworth, J.A., 1998. Cortisol and hypertension. Clinical and Experimental Pharmacology and Physiology, 25(S1), pp.S51-S56.

 

Khattab, F.M., Bessar, H., Hassan, M., 2022. Comparative study of mesotherapy using multivitamins versus botulinum toxin in telogen effluvium. Journal of Cosmetic Dermatology, 21(2), pp.560–567.

 

Koyama, T., Kobayashi, K., Hama, T., Murakami, K. and Ogawa, R., 2016. Standardized scalp massage results in increased hair thickness by inducing stretching forces to dermal papilla cells in the subcutaneous tissue. Eplasty, 16, p.e8.

 

Kumar, S., Garg, A., Puri, P., 2018. A comparative study of mesotherapy with minoxidil in androgenetic alopecia. Journal of Cutaneous and Aesthetic Surgery, 11(4), pp.208–214.

 

Kwon, O.S., Han, J.H., Yoo, H.G., Chung, J.H., Cho, K.H., Eun, H.C. and Kim, K.H., 2007. Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). Phytomedicine, 14(7-8), pp.551-555.

 

Mammucari, M., Russo, D., Maggiori, E., Rossi, M., Lugli, M., Marzo, R.D., Migliore, A., Leone, R., Koszela, K., Varrassi, G. and International Expert Panel, 2025. International consensus guidelines on the safe and evidence-based practice of mesotherapy: A multidisciplinary statement. Journal of Clinical Medicine, 14(13), p.4689.

 

McDonald, K.A., Shelley, A.J. and Alavi, A., 2017. A systematic review on oral isotretinoin therapy and clinically observable wound healing in acne patients. Journal of Cutaneous Medicine and Surgery, 21(4), pp.325-333.

 

Md Fadilah, N.I., Shahabudin, N.A., Mohd Razif, R.A., Sanyal, A., Ghosh, A., Baharin, K.I., Ahmad, H., Maarof, M., Motta, A. and Fauzi, M.B., 2024. Discovery of bioactive peptides as therapeutic agents for skin wound repair. Journal of Tissue Engineering, 15, p.20417314241280359.

 

Nassar, A., Abdel‐Aleem, H., Samir, M. and Khattab, F.M., 2022. Efficacy of botulinum toxin A injection in the treatment of androgenic alopecia: A Comparative Controlled Study. Journal of Cosmetic Dermatology, 21(10), pp.4261-4268.

 

Papakonstantinou, E., Roth, M. and Karakiulakis, G., 2012. Hyaluronic acid: A key molecule in skin aging. Dermato-endocrinology, 4(3), pp.253-258.

 

Patel, D.P., Swink, S.M. and Castelo-Soccio, L., 2017. A review of the use of biotin for hair loss. Skin appendage disorders, 3(3), pp.166-169.

 

Pickart, L. and Margolina, A., 2018. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International journal of molecular sciences, 19(7), p.1987.

 

Rushton, D.H., 2002. Nutritional factors and hair loss. Clinical and experimental dermatology, 27(5), pp.396-404.

 

Rushton, D.H., 2021.  Nutritional factors and hair loss. Clinical and Experimental Dermatology, 46(3), pp. 561–566. https://doi.org/10.1111/ced.14438

 

Schneider, M.R., Schmidt-Ullrich, R. and Paus, R., 2009. The hair follicle as a dynamic miniorgan. Current Biology, 19(3), pp. R132–R142.

 

Shome, D., Kapoor, R., Doshi, K., Patel, G., Vadera, S. and Kumar, V., 2021. Comparison of QR 678® & QR678® Neo as monotherapy and as combination therapy with 5% Minoxidil solution and oral Finasteride in the treatment of male androgenetic alopecia—Which is better?. Journal of cosmetic dermatology, 20(6).

 

Sivagnanam, G., 2010. Mesotherapy–The French Connection. Journal of pharmacology & pharmacotherapeutics, 1(1), p.4.

 

Sobhy, N., Aly, H., El Shafee, A. and El Deeb, M., 2013. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of

androgenetic alopecia in males. Our Dermatology Online, 4(1), p.40.

 

Soga, S., Koyama, T., Mikoshi, A., Jinzaki, M., Arafune, T., Kawashima, M., Kobayashi, K. and Shinmoto, H., 2021. Quantitative analysis of the anatomical changes in the scalp and hair follicles in androgenetic alopecia using magnetic resonance imaging. Skin Research and Technology, 27(1), pp.56-61.

 

Steiner, B.M. and Berry, D.C., 2022. The regulation of adipose tissue health by estrogens. Frontiers in Endocrinology, 13, p.889923.

 

Sudeep, H.V., Rashmi, S., Jestin, T.V., Richards, A., Gouthamchandra, K. and Shyamprasad, K., 2023. Oral and topical administration of a standardized saw palmetto oil reduces hair Fall and improves the hair growth in androgenetic alopecia subjects–a 16-week randomized, placebo-controlled study. Clinical, Cosmetic and Investigational Dermatology, pp.3251-3266.

 

Torkamani, N., Rufaut, N., Jones, L. and Sinclair, R., 2017. The arrector pili muscle is the bridge between the follicular stem cell niche and the interfollicular epidermis. Anatomical science international, 92(1), pp.151-158.

 

Uzel, B.P.C., Takano, G.H.S., Chartuni, J.C.N., Cesetti, M.V., Gavioli, C.F.B., Lemes, A.M. and Costa, I.M.C., 2021. Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: a randomized, placebo‐controlled trial. Dermatologic therapy, 34(1), p.e14622.

 

Varani, J., Dame, M.K., Rittie, L., Fligiel, S.E., Kang, S., Fisher, G.J. and Voorhees, J.J., 2006. Decreased collagen production in chronologically aged skin: roles of age-dependent alteration in fibroblast function and defective mechanical stimulation. The American journal of pathology, 168(6), pp.1861-1868.

 

Quan, T., Wang, F., Shao, Y., Rittié, L., Xia, W., Orringer, J.S., Voorhees, J.J. and Fisher, G.J., 2013. Enhancing structural support of the dermal microenvironment activates fibroblasts, endothelial cells, and keratinocytes in aged human skin in vivo. Journal of Investigative Dermatology, 133(3), pp.658-667.

 

Wan, J., Kim, S.B., Cartier, H., Garson, S., Frank, K., Haykal, D. and Yi, K.H., 2025. A prospective study of exosome therapy for androgenetic alopecia. Aesthetic plastic surgery, pp.1-6.

 

Won, C.H., Kwon, O.S., Kim, Y.K., Kang, Y.J., Kim, B.J., Choi, C.W., Eun, H.C. and Cho, K.H., 2008. Dermal fibrosis in male pattern hair loss: a suggestive implication of mast cells. Archives of dermatological research, 300(3), pp.147-152.

 

Yang, R., Wang, J., Chen, Y., Qu, Y., Zhang, J., Wang, X., Deng, Y., Xu, J. and Yang, J. and Chen, C., 2024. Hormonal changes in PCOS. Journal of Endocrinology, 261(1).

 

Yano, K., Brown, L.F. and Detmar, M., 2001. Control of hair growth and follicle size by VEGF-mediated angiogenesis. The Journal of clinical investigation, 107(4), pp.409-417.

 

 

 

NOTE: This white paper is intended for educational and clinical framework purposes only. It does not constitute peer-reviewed research and should not be used as a substitute for medical advice. The content is based on published literature, expert interpretation, and clinical practice trends. All therapeutic decisions should be made in accordance with local regulations, patient-specific factors, and professional judgment.

 

Author the author

 

Shannel Watson, MSc Biomedical Sciences, Clinical Trichologist, specialises in evidence-based approaches to hair and scalp disorders. With clinical experience in mesotherapy and the integration of adjunctive therapies, including nutritional correction, topical agents, and light-based devices, she bridges scientific research with patient-centred practice. Her work aims to establish clear, biologically grounded protocols that support both clinical safety and innovation in trichology.